Fisher & Paykel Healthcare Corp Ltd (ASX:FPH) shares sink on results release

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price has sunk lower in early trade following the release of its full year results.

At the time of writing the sleep treatment company’s shares are down 4% to $11.70.

What did Fisher & Paykel Healthcare report?

Fisher & Paykel Healthcare reported a record net profit after tax of NZ$190.2 million on record operating revenue of NZ$980.8 million. This was a 12% and 10% increase, respectively, on FY 2017’s result.

The main driver of growth for the company was its Hospital segment. Sales in the segment grew 14% on the prior corresponding period to NZ$572.1 million. Homecare segment sales grew 4% to NZ$398.1 million during the period.

The market was expecting net profit after tax of $188.7 million, so this profit result can be considered a slight beat.

As was its final dividend which was increased to 12.5 cents per share versus expectations of 11.3 cents per share.

So why is its share price sinking lower?

While the company may have outperformed expectations in FY 2018, it has fallen short with its guidance for FY 2019.

According to the Bloomberg consensus estimate, the market was expecting guidance of NZ$1,110 million on the top line and NZ$216 million on the bottom line. Whereas management’s guidance is for revenue of NZ$1,050 million and profit of NZ$210 million.

Considering the premium of 40x full year earnings that its shares traded at prior today, this growth is clearly not considered to be strong enough.

I would have to agree. Especially when rival Resmed Inc (ASX: RMD) is growing its bottom line at a far quicker rate on a much larger base. Furthermore, its shares are actually trading on a lower multiple as well.

In light of this, I would suggest invests skip Fisher & Paykel Healthcare and consider ResMed. Alternatively, healthcare stars Cochlear Limited (ASX: COH) and CSL Limited (ASX: CSL) could also be better options.

As well as ResMed, Cochlear, and CSL, I think these up and comers could be stars of the future.

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!